CN116138459B - Easily-dispersible and easily-absorbable calcium powder composition and preparation method thereof - Google Patents
Easily-dispersible and easily-absorbable calcium powder composition and preparation method thereof Download PDFInfo
- Publication number
- CN116138459B CN116138459B CN202310426080.6A CN202310426080A CN116138459B CN 116138459 B CN116138459 B CN 116138459B CN 202310426080 A CN202310426080 A CN 202310426080A CN 116138459 B CN116138459 B CN 116138459B
- Authority
- CN
- China
- Prior art keywords
- calcium
- parts
- powder composition
- dispersible
- readily
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000011575 calcium Substances 0.000 title claims abstract description 177
- 229910052791 calcium Inorganic materials 0.000 title claims abstract description 177
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title claims abstract description 175
- 239000000203 mixture Substances 0.000 title claims abstract description 74
- 239000000843 powder Substances 0.000 title claims abstract description 64
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 238000005469 granulation Methods 0.000 claims abstract description 53
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims abstract description 39
- 239000001354 calcium citrate Substances 0.000 claims abstract description 39
- 235000013337 tricalcium citrate Nutrition 0.000 claims abstract description 39
- 230000003179 granulation Effects 0.000 claims abstract description 31
- 230000002745 absorbent Effects 0.000 claims abstract description 19
- 239000002250 absorbent Substances 0.000 claims abstract description 19
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims description 52
- 108010001441 Phosphopeptides Proteins 0.000 claims description 36
- 239000005018 casein Substances 0.000 claims description 33
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 33
- 235000021240 caseins Nutrition 0.000 claims description 33
- 229920001100 Polydextrose Polymers 0.000 claims description 26
- 239000001259 polydextrose Substances 0.000 claims description 26
- 235000013856 polydextrose Nutrition 0.000 claims description 26
- 229940035035 polydextrose Drugs 0.000 claims description 26
- 108010046377 Whey Proteins Proteins 0.000 claims description 24
- 102000007544 Whey Proteins Human genes 0.000 claims description 24
- 238000007873 sieving Methods 0.000 claims description 21
- 239000004386 Erythritol Substances 0.000 claims description 19
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 19
- 229940009714 erythritol Drugs 0.000 claims description 19
- 235000019414 erythritol Nutrition 0.000 claims description 19
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical group OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 19
- 238000001035 drying Methods 0.000 claims description 18
- 239000000853 adhesive Substances 0.000 claims description 17
- 230000001070 adhesive effect Effects 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 235000021119 whey protein Nutrition 0.000 claims description 17
- 238000002156 mixing Methods 0.000 claims description 15
- 229920001817 Agar Polymers 0.000 claims description 14
- 239000008272 agar Substances 0.000 claims description 14
- 235000010419 agar Nutrition 0.000 claims description 14
- 239000007864 aqueous solution Substances 0.000 claims description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 14
- 239000008518 lycium barbarum polysaccharide Substances 0.000 claims description 13
- 238000005303 weighing Methods 0.000 claims description 12
- 230000007065 protein hydrolysis Effects 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 8
- 238000000889 atomisation Methods 0.000 claims description 7
- 238000007599 discharging Methods 0.000 claims description 7
- 239000000945 filler Substances 0.000 claims description 7
- 239000008213 purified water Substances 0.000 claims description 7
- 239000000375 suspending agent Substances 0.000 claims description 6
- 239000006096 absorbing agent Substances 0.000 claims description 4
- 238000011068 loading method Methods 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims 2
- 238000000576 coating method Methods 0.000 claims 2
- 238000010521 absorption reaction Methods 0.000 abstract description 55
- 150000001875 compounds Chemical class 0.000 abstract description 13
- 239000002245 particle Substances 0.000 abstract description 12
- 239000002994 raw material Substances 0.000 abstract description 11
- 239000003623 enhancer Substances 0.000 abstract description 7
- 238000000034 method Methods 0.000 abstract description 7
- 230000036541 health Effects 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 4
- 230000009747 swallowing Effects 0.000 abstract description 3
- 208000019505 Deglutition disease Diseases 0.000 abstract description 2
- 239000011230 binding agent Substances 0.000 abstract description 2
- 239000006185 dispersion Substances 0.000 abstract description 2
- 230000006872 improvement Effects 0.000 abstract description 2
- 235000008452 baby food Nutrition 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 229960005069 calcium Drugs 0.000 description 153
- 230000000694 effects Effects 0.000 description 18
- 230000000052 comparative effect Effects 0.000 description 14
- 241000700159 Rattus Species 0.000 description 12
- 230000037182 bone density Effects 0.000 description 12
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 150000004676 glycans Chemical class 0.000 description 10
- 229920001282 polysaccharide Polymers 0.000 description 10
- 239000005017 polysaccharide Substances 0.000 description 10
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
- 235000017784 Mespilus germanica Nutrition 0.000 description 7
- 244000182216 Mimusops elengi Species 0.000 description 7
- 235000000560 Mimusops elengi Nutrition 0.000 description 7
- 235000007837 Vangueria infausta Nutrition 0.000 description 7
- 239000005862 Whey Substances 0.000 description 7
- 210000000988 bone and bone Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000008901 benefit Effects 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 230000001502 supplementing effect Effects 0.000 description 6
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 229910000019 calcium carbonate Inorganic materials 0.000 description 5
- 235000010216 calcium carbonate Nutrition 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 229910001424 calcium ion Inorganic materials 0.000 description 4
- 229940069978 calcium supplement Drugs 0.000 description 4
- 238000013329 compounding Methods 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- 229910052725 zinc Inorganic materials 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 244000241838 Lycium barbarum Species 0.000 description 3
- 235000015459 Lycium barbarum Nutrition 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 235000011090 malic acid Nutrition 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 235000019764 Soybean Meal Nutrition 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 229940124532 absorption promoter Drugs 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000003321 atomic absorption spectrophotometry Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000037180 bone health Effects 0.000 description 2
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 2
- 239000001527 calcium lactate Substances 0.000 description 2
- 229960002401 calcium lactate Drugs 0.000 description 2
- 235000011086 calcium lactate Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 229940116298 l- malic acid Drugs 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000004455 soybean meal Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- 235000005282 vitamin D3 Nutrition 0.000 description 2
- 239000011647 vitamin D3 Substances 0.000 description 2
- 229940021056 vitamin d3 Drugs 0.000 description 2
- 239000011746 zinc citrate Substances 0.000 description 2
- 235000006076 zinc citrate Nutrition 0.000 description 2
- 229940068475 zinc citrate Drugs 0.000 description 2
- GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- OPSXJNAGCGVGOG-DKWTVANSSA-L Calcium L-aspartate Chemical compound [Ca+2].[O-]C(=O)[C@@H](N)CC([O-])=O OPSXJNAGCGVGOG-DKWTVANSSA-L 0.000 description 1
- 206010006956 Calcium deficiency Diseases 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 239000004470 DL Methionine Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- DKKCQDROTDCQOR-UHFFFAOYSA-L Ferrous lactate Chemical compound [Fe+2].CC(O)C([O-])=O.CC(O)C([O-])=O DKKCQDROTDCQOR-UHFFFAOYSA-L 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 206010070538 Gestational hypertension Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010039984 Senile osteoporosis Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000003569 TRPV6 Human genes 0.000 description 1
- 101150096736 TRPV6 gene Proteins 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000019804 backache Diseases 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229960005084 calcitriol Drugs 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- 229940034055 calcium aspartate Drugs 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- 230000003913 calcium metabolism Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- MKJXYGKVIBWPFZ-CEOVSRFSSA-L calcium;(2s)-2-hydroxypropanoate Chemical compound [Ca+2].C[C@H](O)C([O-])=O.C[C@H](O)C([O-])=O MKJXYGKVIBWPFZ-CEOVSRFSSA-L 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical group [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000005115 demineralization Methods 0.000 description 1
- 230000002328 demineralizing effect Effects 0.000 description 1
- 238000001739 density measurement Methods 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000004225 ferrous lactate Substances 0.000 description 1
- 235000013925 ferrous lactate Nutrition 0.000 description 1
- 229940037907 ferrous lactate Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008202 granule composition Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 235000019533 nutritive sweetener Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/40—Shaping or working of foodstuffs characterised by the products free-flowing powder or instant powder, i.e. powder which is reconstituted rapidly when liquid is added
- A23P10/47—Shaping or working of foodstuffs characterised by the products free-flowing powder or instant powder, i.e. powder which is reconstituted rapidly when liquid is added using additives, e.g. emulsifiers, wetting agents or dust-binding agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The application provides an easily-dispersible and easily-absorbable calcium powder composition and a preparation method thereof, and relates to the technical field of health-care products. The raw materials of the calcium powder composition comprise a calcium source, a binding agent and a calcium absorption enhancer. The calcium source is superfine powder calcium citrate which passes through a 1250-mesh sieve, can be applied to infant food, and is easy to disperse and absorb by human bodies; the calcium-promoted absorbent is a compound composition, and has more remarkable synergistic effect and more effective improvement of the absorption rate of calcium compared with a single calcium-promoted absorbent. The composition is prepared by using a mature fluidized bed granulation process, has proper particle size and dimension, and meets the requirements of Chinese pharmacopoeia. The calcium powder composition has the characteristics of easy dispersion, easy swallowing in the mouth, easy absorption, health and no sugar, and is suitable for pregnant women, children and middle-aged and elderly people with dysphagia.
Description
Technical Field
The invention relates to the technical field of health products, in particular to an easily-dispersible and easily-absorbable calcium powder composition and a preparation method thereof.
Background
Calcium is a main element composing human bones, and is sufficient to provide nutrition for the calcium, thereby playing an important role in maintaining bone health of people in various stages of life. Calcium deficiency can lead to a variety of diseases and complications in the human body. Specifically, for different specific crowds, if the human body is insufficient in calcium intake, the middle-aged and the elderly are easy to have symptoms such as fracture, cramp, bone pain, osteoporosis and the like; the intake of the pregnant woman lacking in calcium is easy to induce muscle spasm, waist soreness and backache, absentmindedness and severe gestational hypertension; the lack of calcium in teenagers and children can affect the development of bones, inappetence, and the like. Therefore, adequate calcium intake has been a fundamental measure for maintaining bone health and preventing bone diseases. As such, children, pregnant women, and the elderly are also recommended by modern medicine as specific populations for calcium supplementation. Along with the improvement of the living standard and health consciousness of people, the cognition of people on health-care food is gradually clear, and timely calcium supplement can gradually become daily living habit of people. It is expected that more and more calcium preparations will enter the market, the calcium preparation market is expected to be further subdivided, and a good development opportunity is provided for new enterprises. Therefore, the development of the easily-dispersed and easily-absorbed calcium supplementing composition and the preparation method thereof have broad prospects and great significance.
The ideal calcium supplement should have the characteristics of convenient eating, fast digestion, good absorption, less side effects and the like. Currently, the main stream of calcium-supplementing preparations on the market still mainly comprises "molecular calcium", such as calcium carbonate, calcium phosphate, calcium citrate, and the dosage forms of molecular calcium products include: chewable tablets, capsules, effervescent tablets, granules, medicinal granules and the like. Although molecular calcium has the advantages of easily available raw materials, low cost and the like, the molecular calcium cannot be directly absorbed by human bodies, and can be converted into absorbable calcium by digestive juice and enzyme, so that the absorption rate is very low, the effective utilization rate of the calcium is lower than 40%. For example, the digestion and decomposition rate of calcium citrate in vivo depends on factors such as the size, structural compactness, surface properties (morphology, wettability and the like) and the like of the calcium citrate, and calcium citrate molecules with smaller size and larger specific surface area are easier to disperse into intestines and stomach to be absorbed, and finally the absorption and utilization rate of calcium ions of a human body are improved.
As disclosed in chinese patent application 202110130168.4, a calcium supplementing composition and a method for preparing the same, the composition comprising the following components: stachyose, casein phosphopeptide, calcium carbonate, L-calcium lactate, calcium aspartate, mushroom powder and maltodextrin, the invention has the advantages of good calcium supplementing effect, simple preparation process and excellent product stability and solubility, but the calcium supplementing composition provided by the application has low absorptivity and is difficult to increase bone density.
As further disclosed in chinese patent application 201510819478.1, a calcium lactate granule composition suitable for infant calcium supplementation and a method for preparing the same are disclosed, which comprises the following components in parts by weight: 50-90 parts of calcium lactate, 0.5-1 part of zinc citrate, 0.3-1 part of ferrous lactate, 5-10 parts of casein phosphopeptide, 350-400 parts of glucose, 20-40 parts of fructo-oligosaccharide, 5-10 parts of L-malic acid and 10-30 parts of edible traditional Chinese medicine granules for strengthening spleen and tonifying qi, and the preparation method comprises the following steps of: A. preparing edible Chinese medicinal material granules, mixing the raw materials and sterilizing; compared with the prior art, the invention effectively combines the calcium supplement agent and the traditional Chinese medicine, realizes the combination of Chinese and western medicine and food and medicine, promotes the absorption of calcium, iron and zinc by casein phosphopeptide, promotes the digestion and absorption of zinc citrate, promotes the absorption and metabolism by L-malic acid, and promotes the digestion and absorption by the edible traditional Chinese medicine components of strengthening spleen and supplementing qi, and the citrate, the malic acid, the lactate and calcium ions are easy to form metastable calcium salt, inhibit the generation of insoluble calcium, better promote the absorption of calcium, iron and zinc by infants, and achieve the effect of 1+1 > 2, but the effect of increasing the absorption rate of calcium and the bone density is still unsatisfactory.
Aiming at the problems of poor taste, low dispersity, difficult swallowing, low absorptivity, difficult bone density increase and the like of various health care products for improving bone density, the invention aims to find a calcium micro-granulation composition and a preparation method thereof, so that the calcium micro-granulation composition is more convenient and fast to drink or eat by consumers, is easier to orally swallow, and is easier to disperse and absorb.
Disclosure of Invention
Based on the defects existing in the prior art, the application aims at providing the easily-dispersible and easily-absorbable calcium powder composition and the preparation method thereof, and the application adopts a fluidized bed process with mature micro-granulation, so that the prepared composition has the advantages of proper particle size, uniform particles, easy oral administration and swallowing, easy absorption, better edible experience, high absorption rate of the obtained calcium composition and remarkable effect of increasing bone density.
In order to achieve the purpose, the application adopts the following technical scheme:
the easily dispersible and easily absorbable calcium powder composition comprises the following components in parts by weight: 35-55 parts of a calcium source, 0.5-3 parts of a calcium promoter and 5-20 parts of an adhesive;
the calcium source is calcium citrate, and the calcium citrate is ultrafine powder capable of passing through a 1250-mesh sieve.
The calcium-promoted absorbent comprises casein phosphopeptide.
As some preferred embodiments, the calcium boost absorber further comprises whey proteolytic peptides or/and lycium barbarum polysaccharides;
preferably, the calcium-promoted absorbent is a mixture of casein phosphopeptide, whey protein hydrolysis peptide and Lycium barbarum polysaccharide in a mass ratio of 1:1:1.
The adhesive is polydextrose.
In some preferred embodiments, the mass ratio of calcium citrate to polydextrose is from 25:2 to 8.
As some preferred embodiments, the readily dispersible, readily absorbable calcium powder compositions have a moisture content of 0.5 to 8 weight percent.
As some preferred embodiments, the easily dispersible and easily absorbable calcium powder composition further comprises 20-40 parts of filler and 1-3 parts of suspending agent;
the filler is erythritol;
the suspending agent is agar.
As some preferred embodiments, the easily dispersible and easily absorbable calcium powder composition comprises the following components in parts by weight:
35-55 parts of calcium citrate;
5-20 parts of polydextrose;
20-40 parts of erythritol;
0.5-3 parts of calcium-promoted absorbent;
1-3 parts of agar;
the calcium-promoted absorbent is a mixture of casein phosphopeptide, whey protein hydrolysis peptide and Lycium barbarum polysaccharide in a mass ratio of 1:1:1.
The application also provides a preparation method of the easily-dispersible and easily-absorbable calcium powder composition, which comprises the following steps:
(1) Preparing an adhesive: sieving the adhesive, dispersing the adhesive with the formula amount in purified water with the formula amount of 40%, and stirring to dissolve the adhesive into an aqueous solution;
(2) Granulating: weighing and loading a calcium source, a suspending agent and a filler in the dosage of the formula into a stirrer, and uniformly mixing to obtain a mixture; standby; granulating the mixture by using the aqueous solution prepared in the step (1) on a fluidized bed, drying, and sieving once to obtain pre-micro granulating powder;
(3) Mixing the pre-micro granulation powder obtained in the step (2) with a calcium promoter, sieving again, and discharging to obtain a calcium micro granulation composition;
the number of the sieves described in the above step (1) is 10 to 30 mesh, preferably 20 mesh.
The granulation conditions in the step (2) are as follows: the temperature is 45-65 ℃; the atomization pressure is 0.12Mpa-0.3Mpa, and the air inlet frequency is 20 Hz-35 Hz; the number of the first pass is 10-30 meshes, preferably 20 meshes; the number of the re-screening is 10-30 meshes, preferably 20 meshes.
The drying conditions in the step (2) are as follows: the air inlet temperature is 40-60 ℃ and the air inlet frequency is 20-35Hz.
When the water content of the micro-granulation is 0.5-8%, a more uniform granulation morphology can be obtained in the micro-granulation.
The application uses calcium citrate as a calcium source:
calcium citrate, commonly referred to as tricalcium citrate, is also known as calcium citrate. As an organic acid calcium, the calcium carbonate has higher solubility and bioavailability than inorganic acid calcium such as calcium carbonate, tricalcium citrate and the like, has no stimulation to intestines and stomach, does not need to be neutralized by gastric acid, and can be directly absorbed by human body. For example, tan Hui provides good therapeutic effects on osteoporosis by calcium citrate, which does not produce CO in the gastrointestinal tract 2 Therefore, the adverse reactions such as dyspepsia, abdominal distension, constipation and the like are reduced, and the traditional Chinese medicine composition is particularly suitable for long-term use of senile osteoporosis patients. Calcium citrate has been widely used as a food additive and a nutrition enhancer, and is the first choice for food-based calcium supplements.
Erythritol is used as a filler or sweetener in the present application:
erythritol is a novel nutritive sweetener and is characterized by good heat stability, small hygroscopicity, low freezing point, low calorific value and cool feel. The characteristics of the composition lead the composition to be widely applied to the fields of foods, medicines, cosmetics and the like. Wherein, because the erythritol has very low calorie and is called as a sweetener with zero calorific value, the erythritol can be used for producing various low-calorie health-care foods and beverages; in the field of medicine, erythritol can be used as a flavoring agent of medicines and an excipient of tablets, can effectively improve the taste of products, and is also beneficial to forming uniform granulation in the fluidized bed granulation process.
Casein phosphopeptides are used as one of the calcium-promoted absorbers:
casein phosphopeptide (CPP) has been widely studied as a known phosphopeptide calcium-supplementing preparation, its calcium absorption-promoting activity and mechanism. The absorption pathway of calcium in mammals can be divided into the saturated transcellular pathway (i.e., active absorption) and the cellular alternative pathway (i.e., passive absorption), and the main way of calcium absorption depends on the body's calcium content. The phosphopeptide has a remarkable effect on binding metal ions due to the special negative charge structure, calcium ions are easy to be combined with the phosphopeptide to form a peptide-calcium complex, the peptide-calcium complex is integrally transported into cells through a small peptide transportation path, the small peptide is used as a carrier for calcium transportation, and the calcium absorption is promoted and is not dependent on TRPV6 calcium ion channels and 1, 25-dihydroxyvitamin D3 to be absorbed by human bodies, so that the function of substituting the vitamin D3 can be achieved to a certain extent. Meanwhile, various research data show that the lycium barbarum polysaccharide and the whey protein hydrolysis peptide have the same efficacy as CPP, and can promote the absorption of free calcium by human bodies. Therefore, the calcium absorption and diffusion transportation are promoted by adding the calcium absorption promoter, so that the absorption rate of the calcium is increased.
It has the following advantages:
1. the casein phosphopeptide can keep calcium in a free state and promote the passive absorption of calcium; 2. promoting the absorption and utilization of other divalent mineral nutrients such as iron, zinc and the like, and overcoming the potential adverse effect of calcium on the absorption of iron and zinc; 3. the casein phosphopeptide can also weaken the action of osteoclasts and inhibit bone resorption, thereby improving the bone calcium content; 4. can also combine calcium ions at the caries site, lighten the demineralization of enamel and achieve the effect of anticarious. Alternatively, the whey protein-hydrolyzing peptide and the matrimony vine polysaccharide also have the effect of promoting calcium absorption.
The application uses polydextrose as a binder:
has the following advantages: 1. changing physical and chemical properties of the substance; 2. changing the reactivity of the envelope; 3. has low calorie health food characteristics; 4. has necessary volume, improves the taste of food, improves oily taste, and is favorable for granulation and dispersion.
Compared with the prior art, the application has the following beneficial effects:
1. according to the calcium powder composition, as the raw material calcium citrate is ultrafine powder capable of passing through a 1250-mesh sieve, the obtained micro-granulation has proper granulation structure and size, and a proper fluidized bed drying process, so that the stability is higher and the granulation dispersity is better; and the effect of remarkably improving the calcium absorption rate of the human body is achieved by adding a proper amount of calcium-promoting absorbent and compounding.
The calcium powder composition provided by the application has reasonable components and proportions, and has good effect of increasing bone density as a calcium supplementing product;
the calcium powder composition provided by the application is uniform and fine in granulation, moderate in hardness, free of peculiar smell, suitable for oral administration, capable of being rapidly taken into the throat, good in dispersibility, smooth in mouth, free of uncomfortable feeling, good in calcium absorption effect, and suitable for pregnant women, children and middle-aged and elderly people with dysphagia.
Detailed Description
The present application is described in detail below with reference to examples, but the present application is not limited to these examples.
Unless otherwise indicated, all starting materials in the examples of the present application were purchased commercially.
Example 1A readily dispersible, readily absorbable calcium powder composition and method of making same
The raw materials comprise the following components in parts by weight:
50 parts of calcium citrate;
10 parts of polydextrose;
37.8 parts of erythritol;
1.2 parts of calcium-promoted absorbent;
agar 1 part.
Wherein the calcium absorption enhancer comprises a mixture of casein phosphopeptide, whey protein hydrolysis peptide and Lycium barbarum polysaccharide in a mass ratio of 1:1:1.
The preparation method comprises the following steps:
(1) Preparing an adhesive: sieving polydextrose with 20 mesh sieve, dispersing polydextrose with 40% of formula amount in purified water, stirring and dissolving to obtain aqueous solution;
(2) Granulating: weighing calcium citrate, agar and erythritol with quantitative formula in a stirrer, and uniformly mixing to obtain a mixture for later use; granulating the calcium citrate mixture by using the aqueous solution prepared in the step (1) on a fluidized bed, drying, and sieving with a 20-mesh sieve once to obtain pre-micro granulating powder;
(3) Mixing the pre-micro granulation powder obtained in the step (2) with a calcium promoter, sieving with a 20-mesh sieve again, and discharging to obtain a calcium micro granulation composition;
the granulation conditions in the step (2) are as follows: the temperature is 60 ℃; the atomization pressure is 0.3Mpa, and the air inlet frequency is 28Hz; the drying conditions are as follows: the air inlet temperature is 55 ℃, the air inlet frequency is 30Hz, and the water content of the micro-granulation is 2.2wt%.
Example 2A readily dispersible, absorbable calcium powder composition and method of making same
The raw materials comprise the following components in parts by weight:
50 parts of calcium citrate;
6 parts of polydextrose;
41.8 parts of erythritol;
1.2 parts of calcium-promoted absorbent;
agar 1 part.
Wherein the calcium absorption enhancer comprises a mixture of casein phosphopeptide, whey protein hydrolysis peptide and Lycium barbarum polysaccharide in a mass ratio of 1:1:1.
The preparation method comprises the following steps:
(1) Preparing an adhesive: sieving polydextrose with 20 mesh sieve, dispersing polydextrose with 40% of formula amount in purified water, stirring and dissolving to obtain aqueous solution;
(2) Granulating: weighing calcium citrate, agar and erythritol with quantitative formula in a stirrer, and uniformly mixing to obtain a mixture for later use; granulating the calcium citrate mixture by using the aqueous solution prepared in the step (1) on a fluidized bed, drying, and sieving with a 20-mesh sieve once to obtain pre-micro granulating powder;
(3) Mixing the pre-micro granulation powder obtained in the step (2) with a calcium absorption promoter, sieving with a 20-mesh sieve again, and discharging to obtain calcium micro granulation composition powder;
the granulation conditions in the step (2) are as follows: the temperature is 60 ℃; the atomization pressure is 0.3Mpa, and the air inlet frequency is 28Hz; the drying conditions are as follows: the air inlet temperature is 55 ℃, the air inlet frequency is 30Hz, and the water content of the micro-granulation is 1.7wt%.
Example 3A readily dispersible, absorbable calcium powder composition and method of making same
The raw materials comprise the following components in parts by weight:
50 parts of calcium citrate;
12 parts of polydextrose;
35.8 parts of erythritol;
1.2 parts of calcium-promoted absorbent;
agar 1 part.
Wherein the calcium absorption enhancer comprises a mixture of casein phosphopeptide, whey protein hydrolysis peptide and Lycium barbarum polysaccharide in a mass ratio of 1:1:1.
The preparation method comprises the following steps:
(1) Preparing an adhesive: sieving polydextrose with 20 mesh sieve, dispersing polydextrose with 40% of formula amount in purified water, stirring and dissolving to obtain aqueous solution;
(2) Granulating: weighing calcium citrate, agar and erythritol with quantitative formula in a stirrer, and uniformly mixing to obtain a mixture for later use; granulating the calcium citrate mixture by using the aqueous solution prepared in the step (1) on a fluidized bed, drying, and sieving with a 20-mesh sieve once to obtain pre-micro granulating powder;
(3) Mixing the pre-micro granulation powder obtained in the step (2) with a calcium promoter, sieving with a 20-mesh sieve again, and discharging to obtain a calcium micro granulation composition;
the granulation conditions in the step (2) are as follows: the temperature is 60 ℃; the atomization pressure is 0.3Mpa, and the air inlet frequency is 28Hz; the drying conditions are as follows: the air inlet temperature is 55 ℃, the air inlet frequency is 30Hz, and the water content of the micro-granulation is 2.6wt%.
Example 4A readily dispersible, absorbable calcium powder composition and method of making same
The raw materials comprise the following components in parts by weight:
50 parts of calcium citrate;
14 parts of polydextrose;
33.8 parts of erythritol;
1.2 parts of calcium-promoted absorbent;
agar 1 part.
Wherein the calcium absorption enhancer comprises a mixture of casein phosphopeptide, whey protein hydrolysis peptide and Lycium barbarum polysaccharide in a mass ratio of 1:1:1.
The preparation method comprises the following steps:
(1) Preparing an adhesive: sieving polydextrose with 20 mesh sieve, dispersing polydextrose with 40% of formula amount in purified water, stirring and dissolving to obtain aqueous solution;
(2) Granulating: weighing calcium citrate, agar and erythritol with quantitative formula in a stirrer, and uniformly mixing to obtain a mixture for later use; granulating the calcium citrate mixture by using the aqueous solution prepared in the step (1) on a fluidized bed, drying, and sieving with a 20-mesh sieve once to obtain pre-micro granulating powder;
(3) Mixing the pre-micro granulation powder obtained in the step (2) with a calcium promoter, sieving with a 20-mesh sieve again, and discharging to obtain a calcium micro granulation composition;
the granulation conditions in the step (2) are as follows: the temperature is 60 ℃; the atomization pressure is 0.2Mpa, and the air inlet frequency is 28Hz; the drying conditions are as follows: the air inlet temperature is 55 ℃, the air inlet frequency is 30Hz, and the water content of the micro-granulation is 2.0wt%.
Example 5A readily dispersible, readily absorbable calcium powder composition and method of making same
The raw materials comprise the following components in parts by weight:
50 parts of calcium citrate;
16 parts of polydextrose;
31.8 parts of erythritol;
1.2 parts of calcium-promoted absorbent;
agar 1 part.
Wherein the calcium absorption enhancer comprises a mixture of casein phosphopeptide, whey protein hydrolysis peptide and Lycium barbarum polysaccharide in a mass ratio of 1:1:1.
The preparation method comprises the following steps:
(1) Preparing an adhesive: sieving polydextrose with 20 mesh sieve, dispersing polydextrose with 40% of formula amount in purified water, stirring and dissolving to obtain aqueous solution;
(2) Granulating: weighing calcium citrate, agar and erythritol with quantitative formula in a stirrer, and uniformly mixing to obtain a mixture for later use; granulating the calcium citrate mixture by using the aqueous solution prepared in the step (1) on a fluidized bed, drying, and sieving with a 20-mesh sieve once to obtain pre-micro granulating powder;
(3) Mixing the pre-micro granulation powder obtained in the step (2) with a calcium promoter, sieving with a 20-mesh sieve again, and discharging to obtain a calcium micro granulation composition;
the granulation conditions in the step (2) are as follows: the temperature is 60 ℃; the atomization pressure is 0.2Mpa, and the air inlet frequency is 28Hz; the drying conditions are as follows: the air inlet temperature is 55 ℃, the air inlet frequency is 30Hz, and the water content of the micro-granulation is 1.8wt%.
Comparative example 1
The only difference from example 1 is that the calcium citrate in the starting material was replaced by calcium carbonate and the moisture content of the micropellet was 2.4 wt.%, the other components and contents and the preparation method were the same as in example 1.
Comparative example 2
The only difference from example 1 is that the calcium citrate in the raw material was replaced with calcium gluconate and the moisture content of the micro-granulation was 2.7. 2.7 wt%, the other components and contents and the preparation method were the same as in example 1.
Comparative example 3
The only difference from example 1 is that the polydextrose in the raw material was replaced by inulin, the moisture content of the micro-granulation was 1.7. 1.7wt%, and other components and contents and the preparation method were the same as in example 1.
Comparative example 4
The only difference from example 1 is that the polydextrose in the starting material was replaced by a resistant dextrin, the moisture content of the microgranulate was 2.1. 2.1 wt%, and the other components and contents and the preparation method were the same as in example 1.
Comparative example 5
The only difference from example 1 is that the inlet frequency of the fluidized bed granulation was 32Hz, the inlet frequency of the drying was 34Hz, the water content of the micro-granulation was 1.5wt%, and other components and contents and the preparation method were the same as in example 1.
Comparative example 6
The only difference from example 1 is that the inlet frequency of the fluidized bed granulation is 24Hz, the inlet frequency of the drying is 26Hz, the water content of the micro-granulation is 3.5. 3.5 wt%, and other components and contents and the preparation method are the same as those of example 1.
And (3) effect verification:
1. appearance and mouthfeel test
TABLE 1 sensory evaluation criteria Table
Table 2 sample calcium micro-granulation oral mouthfeel test table
As can be seen from Table 2, the calcium micro-pelletization samples prepared in examples 1-5 were better in appearance and taste and higher in overall score as compared with examples 1-5 and comparative examples 1-6; examples 1-5 in comparison, the calcium micro-granulation samples prepared in example 1 had the best appearance and mouthfeel; in the comparison of the examples and the comparative examples, the mass ratio of the calcium citrate to the polydextrose is 50:10, the granulating condition is 60 ℃, and the air inlet frequency is 28Hz; the appearance and taste scores are higher under the conditions of 55 ℃ of drying conditions and 30Hz of air inlet frequency. The results demonstrate that the embodiment 1 has more proper particle size and dimension, solves the problems of mouth sticking and choking of the superfine powder, and the novel composition is easy to be dispersed in micro-granulation and easy to be orally taken down to the throat.
2. Flowability and particle size testing
The testing method comprises the following steps:
examples and comparative examples the particle size distribution of calcium micro-granulated samples was measured using a NKT52000-H laser particle sizer. The specific method comprises the following steps:
1. measuring a proper amount of absolute ethyl alcohol, adding the absolute ethyl alcohol into a sample cell to a scale mark, opening the sample cell for circulation, stirring, ultrasonic treatment and the like, and performing background test;
2. adding a small amount of calcium micro-granulation sample into the sample cell after the background test, starting the sample cell to circulate, and after the concentration reaches a preset value, starting to measure sample data, continuously collecting and storing the test data;
3. after the measurement is finished, the device is automatically cleaned for 3 times by absolute ethyl alcohol, so that the device channel is ensured to be clean;
4. computer software gives the particle accumulation percentage value directly.
The results of the measurements are shown in Table 3 below.
TABLE 3 sample micro-granulation flowability and particle size results table
As can be seen from Table 3, examples 1-5 and comparative examples 1-6 were better in fluidity in comparison with the prescription; in the comparison of examples 1-5, the micro-granulation of example 1 was better in flowability, the average particle size was smallest and the particle size distribution was more concentrated; in comparison of example 1 with comparative example 1 and comparative example 2, it is seen that the calcium citrate has better flowability; in comparison between example 1 and comparative examples 3 and 4, it is found that the flowability of polydextrose is better; in comparison between example 1 and comparative examples 5 and 6, it is found that the fine granulation fluidity is improved under the condition of a large air intake frequency, and that the air intake frequency is preferably 32Hz. In summary, example 1 has an optimal micro-granulation flow and particle size range and suitable granulation process conditions.
3. Promote calcium absorption experiment
3.1, experimental animal: the experiment adopts 90 male rats (secondary) with weight of about 65g, and the male rats are purchased from the breeding field of the laboratory animal institute of China medical science academy of sciences, and are randomly divided into 15 groups according to weight after the animal house is fed with basic feed for 1 week, wherein the 15 groups of rats are respectively numbered as blank group, example 1 group, control 2 group, control 3 group, control 4 group, control 5 group, control 6 group, control 7 group, control 8 group, control 9 group, control 10 group, control 11 group, control 12 group and control 13 group. Respectively feeding semisynthetic feeds with different contents and types of calcium promoters.
3.2, grouping animals and feeding: different calcium promoters and combinations thereof were mixed in different doses in basal feed as experimental groups. And (3) measuring the calcium content in the calcium agent sample and the feed by using an atomic absorption spectrophotometry. The formula of the basic feed is as follows: 100 parts of soybean meal, 150 parts of soybean meal, 526 parts of wheat flour, 40 parts of peanut oil, 25 parts of cellulose, 140 parts of starch, 10 parts of mixed vitamin, 5 parts of salt, 2 parts of DL-methionine and 2 parts of choline chloride. The content of vitamin D3 in the basic feed is 1000 IU/kg. The experimental period was 12 weeks. Animals were fed in single cages and were fed ad libitum, with deionized water.
Blank groups, fed only basal feed;
example 1 group, wherein 4g/kg casein phosphopeptide, 4g/kg whey protein and 4g/kg Lycium barbarum polysaccharide are added and weighed respectively on the basis of basic feed to be compounded, the total amount of the compounded powder of the calcium accelerator is 12g/kg, and other feeding conditions are consistent with the blank group;
the control group 1 is respectively added with 2g/kg casein phosphopeptide, 2g/kg whey protein and 2g/kg medlar polysaccharide for compounding on the basis of basic feed, and the total amount of the compounded powder of the calcium accelerator is 6g/kg, and other feeding conditions are consistent with those of the blank group;
the control group 2 is respectively added with 8g/kg casein phosphopeptide, 8g/kg whey protein and 8g/kg medlar polysaccharide for compounding on the basis of basic feed, and the total amount of the calcium accelerator compounding powder is 24g/kg, and other feeding conditions are consistent with those of the blank group;
control 3 groups, namely adding and weighing 12g/kg of calcium accelerator compound powder on the basis of basic feed, wherein the mass ratio of casein phosphopeptide, whey protein and medlar polysaccharide in the compound powder is (2:1:1), and other feeding conditions are consistent with the blank groups;
control group 4, adding and weighing 12g/kg of calcium accelerator compound powder on the basis of basic feed, wherein the mass ratio of casein phosphopeptide, whey protein and medlar polysaccharide in the compound powder is (1:2:1), and other feeding conditions are consistent with the blank group;
control 5 groups, adding and weighing 12g/kg of calcium accelerator compound powder on the basis of basic feed, wherein the mass ratio of casein phosphopeptide, whey protein and medlar polysaccharide in the compound powder is (1:1:2), and other feeding conditions are consistent with the blank groups;
a control group 6, wherein 12g/kg of calcium accelerator compound powder is added and weighed on the basis of basic feed, compared with the control group 2, casein phosphopeptide is replaced by whey hydrolyzed protein, the mass ratio of the whey hydrolyzed protein to the medlar polysaccharide is (2:1), and other feeding conditions are consistent with the blank group;
control 7 groups, namely adding and weighing 12g/kg of calcium accelerator compound powder on the basis of basic feed, wherein casein phosphopeptide replaces whey hydrolyzed protein, the mass ratio of casein phosphopeptide to Lycium barbarum polysaccharide is (2:1), and other feeding conditions are consistent with those of a blank group;
control group 8, adding and weighing 12g/kg of calcium accelerator compound powder on the basis of basic feed, wherein casein phosphopeptide replaces wolfberry polysaccharide, the ratio of casein phosphopeptide to whey hydrolyzed protein is (2:1), and other feeding conditions are consistent with the blank group;
control 9 groups, adding 12g/kg casein phosphopeptide on the basis of basic feed, and keeping other feeding conditions and dosages consistent with those of the blank groups;
control 10 groups, wherein 6g/kg casein phosphopeptide is added on the basis of basic feed, and other feeding conditions are consistent with those of a blank group;
control 11 groups, wherein 24g/kg casein phosphopeptide is added on the basis of basic feed, and other feeding conditions are consistent with those of a blank group;
control group 12, adding 12g/kg whey hydrolyzed protein on the basis of basic feed, and keeping other feeding conditions consistent with the blank group;
control 13 groups, adding 12g/kg of Lycium barbarum polysaccharide on the basis of basic feed, and keeping other feeding conditions consistent with the blank group;
3.3, metabolic assay: the calcium metabolism experiment is carried out on rats at the 4 th week, the feeding amount of 3 days is recorded, the feces are collected for 72 hours, and the calcium content in the feces and the calcium content of the feed before the current feeding are measured by an atomic absorption spectrophotometry.
3.4, animal bone density measurement: after 12 weeks of feeding, the rats were sacrificed and the right femur was removed and baked to constant weight in an oven at 105 ℃. The bone calcium concentration, mid-femur and metaphyseal bone density (BMD) of the rat were measured using an SD-1000 bone densitometer, calibrated with standard bone modules prior to measurement. And (3) measuring serum indexes in the blood of rats of each experimental group by adopting a full-automatic biochemical tester.
3.5, apparent absorption of calcium= (intake of calcium-faecal calcium) intake of calcium x 100%.
TABLE 4 apparent absorption of calcium powders with different calcium promoters
As can be seen from table 4:
(1) The calcium absorption rate of the example group and the control group is obviously higher than that of the blank group, which indicates that the calcium-promoted absorbent can improve the apparent absorption rate of calcium;
(2) The apparent calcium absorption rate of the group 1 is higher than that of the group 3, the group 4 and the group 5, which shows that the apparent calcium absorption rate of the group 1 is higher than that of the compound calcium accelerant with other proportions when the mass ratio of casein phosphopeptide, whey protein and medlar polysaccharide is (1:1:1);
(3) The calcium absorption rate of the embodiment 1 is obviously higher than the apparent calcium absorption rate of the control 6, the control 7 and the control 8, and under the condition of the same dosage of the calcium accelerator, any one of the accelerators is replaced randomly, and the calcium absorption rate is obviously lower than the simultaneous absorption rate of the three calcium accelerators, which indicates that the three calcium absorbers have the characteristic of synergy;
(4) Under the condition of the same addition amount, the calcium absorption rate of the example 1 group is higher than that of the control 9 group, the control 12 group and the control 13 group; control group 1 had higher calcium absorption than control group 10; the calcium absorption rate of the control group 2 is higher than that of the control group 11, and the result shows that the calcium absorption rate of the composite calcium accelerator is obviously higher than that of a single component under the condition of the same dosage of the calcium accelerator;
(5) The control 11 group had a calcium absorption rate similar to that of the control 9 group and was significantly higher than that of the control 10 group, indicating that the preferred 12g/kg casein phosphopeptide was the optimal addition.
Table 5 calcium concentrations in rats of each group supplemented with different calcium promoters, mid-femoral and metaphyseal bone densities
As can be seen from table 5, the bone calcium concentration, mid-femoral and metaphyseal bone density were significantly higher in the rats of example 1 than in the blank (P < 0.05); the index of the control 9 group is higher than that of the control 10 group, and the difference between the index and the control 11 group is not obvious (P is more than 0.05); the indexes of the example 1 group are obviously higher than those of the control 9 group, the control 12 group and the control 13 group (P < 0.05); the indices of example 1 group were significantly higher than those of control 1 group (P < 0.05), and the differences from control 2 group were not significant (P > 0.05); the index of the example 1 group is significantly higher than that of the control 3-5 group and the control 6-8 group (P < 0.05);
TABLE 6 serum indices of groups of rats supplemented with different calcium promoters
As can be seen from Table 6, there was no significant difference in alkaline phosphatase activity (P > 0.05) between the control group and the example 1, and the serum calcium and serum phosphorus concentrations were lower than those of the control group when the control group and the blank group were compared; the index of each of the control 9 group is higher than that of the control 10 group (P < 0.05), and the difference between the index of each of the control 9 group and the control 11 group is not significant (P > 0.05); each index of example 1 was significantly higher than that of control 9, control 12, and control 13 (P < 0.05); the indices of example 1 group were significantly higher than those of control 1 group (P < 0.05), and the differences from control 2 group were not significant (P > 0.05); the index of the example 1 group is significantly higher than that of the control 3-5 group and the control 6-8 group (P < 0.05);
from the above experimental results, it can be seen that:
(1) The apparent calcium absorption rate, calcium concentration, femur midpoint and metaphyseal bone density, serum calcium concentration and serum phosphorus concentration of the rats in the blank group are all obviously lower than those of the control group and the example 1 group, the activity of alkaline phosphatase in the blank group is higher than that of the example 1 group and the control group, the difference of the activity of alkaline phosphatase between the control group and the example 1 is not obvious, which indicates that the calcium-promoted absorbent is favorable for calcium absorption and bone density increase, and the difference of the activity of alkaline phosphatase indicates that the hormone stress reaction in the model body is reduced through the effective increase of the absorption rate of calcium so as to lead the hormone level in the rats to reach an equilibrium state;
(2) The indexes of the embodiment 1 are obviously higher than those of the control 9, the control 12 and the control 13, which shows that the absorption rate of the group calcium of the composite calcium accelerator is obviously higher than that of the calcium accelerator component added alone on the premise of keeping the consistent total addition amount;
(3) The indexes of the embodiment 1 are obviously higher than those of the control 1, the control 3, the control 4 and the control 5, which shows that the adding amount of the compound calcium absorbent of preferably 12g/kg is better than that of other adding amounts or compound proportion experiment groups in the calcium absorption effect of the three components in the mass ratio of (1:1:1);
(4) The indexes of the embodiment 1 are obviously higher than those of the control 6, the control 7 and the control 8, which shows that under the condition of the same dosage of the calcium promoters, the calcium absorption rate of any one of the calcium promoters is obviously lower than that of the three calcium promoters, and the three calcium promoters have the characteristics of synergy.
It will be apparent that the described embodiments are only individual embodiments of the invention, and not all embodiments. All other implementations, which can be made by those skilled in the art without the benefit of the teachings of this invention, are intended to be within the scope of this invention.
Claims (8)
1. An easily dispersible, easily absorbable calcium powder composition characterized by: the coating comprises the following components in parts by weight: 35-55 parts of a calcium source, 0.5-3 parts of a calcium promoter absorber, 5-20 parts of an adhesive, 20-40 parts of a filler and 1-3 parts of a suspending agent;
the calcium source is calcium citrate; the adhesive is polydextrose;
the calcium-promoted absorbent is a mixture of casein phosphopeptide, whey protein hydrolysis peptide and lycium barbarum polysaccharide in a mass ratio of 1:1:1;
the preparation method of the easily dispersible and easily absorbable calcium powder composition comprises the following steps:
(1) Preparing an adhesive: sieving the adhesive, dispersing the adhesive with the formula amount in purified water with the formula amount of 40%, and stirring to dissolve the adhesive into an aqueous solution;
(2) Granulating: weighing and loading a calcium source, a suspending agent and a filler in the dosage of the formula into a stirrer, and uniformly mixing to obtain a mixture; standby; granulating the mixture by using the aqueous solution prepared in the step (1) on a fluidized bed, drying, and sieving once to obtain pre-micro granulating powder;
(3) Mixing the pre-micro granulating powder obtained in the step (2) with a calcium accelerating absorbent, sieving again, and discharging to obtain the easily-dispersible and easily-absorbable calcium powder composition.
2. The readily dispersible, readily absorbable calcium powder composition of claim 1, wherein: the mass ratio of the calcium citrate to the polydextrose is 25:2-8.
3. The readily dispersible, readily absorbable calcium powder composition of claim 1, wherein: the filler is erythritol.
4. The readily dispersible, readily absorbable calcium powder composition of claim 1, wherein: the suspending agent is agar.
5. The readily dispersible, readily absorbable calcium powder composition of claim 1, wherein: the water content of the easily dispersible and easily absorbable calcium powder composition is 0.5-8wt%.
6. The readily dispersible, readily absorbable calcium powder composition of any of claims 1-5, wherein: the coating comprises the following components in parts by weight:
35-55 parts of calcium citrate;
5-20 parts of polydextrose;
20-40 parts of erythritol;
0.5-3 parts of calcium-promoted absorbent;
1-3 parts of agar;
the calcium-promoted absorbent is a mixture of casein phosphopeptide, whey protein hydrolysis peptide and Lycium barbarum polysaccharide in a mass ratio of 1:1:1.
7. The readily dispersible, readily absorbable calcium powder composition of claim 1, wherein: the granulation conditions in the step (2) are as follows: the temperature is 45-65 ℃; the atomization pressure is 0.12Mpa-0.3Mpa, and the air inlet frequency is 20 Hz-35 Hz.
8. The readily dispersible, readily absorbable calcium powder composition of claim 1, wherein: the drying conditions in the step (2) are as follows: the air inlet temperature is 40-60 ℃ and the air inlet frequency is 20-35Hz.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310426080.6A CN116138459B (en) | 2023-04-20 | 2023-04-20 | Easily-dispersible and easily-absorbable calcium powder composition and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310426080.6A CN116138459B (en) | 2023-04-20 | 2023-04-20 | Easily-dispersible and easily-absorbable calcium powder composition and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116138459A CN116138459A (en) | 2023-05-23 |
| CN116138459B true CN116138459B (en) | 2023-08-04 |
Family
ID=86352799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310426080.6A Active CN116138459B (en) | 2023-04-20 | 2023-04-20 | Easily-dispersible and easily-absorbable calcium powder composition and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116138459B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117959361B (en) * | 2024-04-01 | 2024-06-28 | 吉林浩泰健康产业发展股份有限公司 | Pharmaceutical composition for strengthening tendons and bones and preparation method thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07308172A (en) * | 1994-02-01 | 1995-11-28 | Meiji Seika Kaisha Ltd | Casein phosphopeptide-containing food or drink for person having low calcium absorption |
| CN102697802A (en) * | 2012-06-29 | 2012-10-03 | 广东仙乐制药有限公司 | Composite calcium preparation and preparation method thereof |
| JP2015107074A (en) * | 2013-12-04 | 2015-06-11 | テルモ株式会社 | Liquid nutritional supplement |
| JP2016190814A (en) * | 2015-03-31 | 2016-11-10 | 株式会社東洋新薬 | Calcium permeation promoter |
| CN108157878A (en) * | 2018-01-09 | 2018-06-15 | 纽斯葆广赛（广东）生物科技股份有限公司 | A kind of high fine calcium fortification collagen jelly and preparation method thereof |
| CN110024895A (en) * | 2019-04-16 | 2019-07-19 | 山东圣海保健品有限公司 | Oyster calcium gel candy and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016204323A (en) * | 2015-04-27 | 2016-12-08 | フジ日本精糖株式会社 | Osteogenesis promoter |
-
2023
- 2023-04-20 CN CN202310426080.6A patent/CN116138459B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07308172A (en) * | 1994-02-01 | 1995-11-28 | Meiji Seika Kaisha Ltd | Casein phosphopeptide-containing food or drink for person having low calcium absorption |
| CN102697802A (en) * | 2012-06-29 | 2012-10-03 | 广东仙乐制药有限公司 | Composite calcium preparation and preparation method thereof |
| JP2015107074A (en) * | 2013-12-04 | 2015-06-11 | テルモ株式会社 | Liquid nutritional supplement |
| JP2016190814A (en) * | 2015-03-31 | 2016-11-10 | 株式会社東洋新薬 | Calcium permeation promoter |
| CN108157878A (en) * | 2018-01-09 | 2018-06-15 | 纽斯葆广赛（广东）生物科技股份有限公司 | A kind of high fine calcium fortification collagen jelly and preparation method thereof |
| CN110024895A (en) * | 2019-04-16 | 2019-07-19 | 山东圣海保健品有限公司 | Oyster calcium gel candy and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 酪蛋白磷酸肽（CPP）对大鼠钙吸收利用的影响;张亚非，周羽并，吴凤兰，张明珠，张纫华，于江虹;营养学报(01);第73-77页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116138459A (en) | 2023-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106135890A (en) | A kind of alimentation composition contributing to bony articulation health | |
| CN101268835B (en) | Nutrition high calcium medicinal granule for children and preparing technique | |
| CN104068306B (en) | Health food for improving bone density and preparation method of health food | |
| CN102318835A (en) | Composition for reducing bone loss and preparation method thereof | |
| CN116138459B (en) | Easily-dispersible and easily-absorbable calcium powder composition and preparation method thereof | |
| CN101138570A (en) | Multiple vitamin and mineral composition chewing tablet | |
| CN106912689A (en) | A kind of gestational period feed addictive and feed | |
| CN102415447B (en) | Calcium supplement electuary for infants and preparation process thereof | |
| CN101904507A (en) | Ferrous bisglycinate chelate nutritional composition and application thereof | |
| CN103404865A (en) | Nutritional meal replacement powder with effect of reducing weight and fat and preparation method thereof | |
| CN110151715A (en) | A kind of Biocal and preparation method thereof that lactating female is applicable | |
| CN101279089B (en) | Donkey-hide gelatin calcium composition and preparing process thereof | |
| CN108740305B (en) | Special calcium tablet for perinatal dairy cows and preparation method thereof | |
| CN109394745A (en) | A kind of composition comprising L-carnitine and beta-hydroxy-butanoic acid compound | |
| CN109247482A (en) | Diabetic's solid beverage and preparation method thereof | |
| CN100490896C (en) | Chewing tablet for discharging lead, and preparation method | |
| CN102911068A (en) | L-carnitine L-malate, and preparation method and application thereof | |
| CN111493221A (en) | Traditional Chinese medicine feed additive for improving animal immunity and preparation method thereof | |
| CN110292177A (en) | A kind of composition and its preparation method and application promoting children's bone growth and development | |
| CN105533699A (en) | Compound for supplementing zinc and vitamin in children as well as preparation method and application thereof | |
| CN101129406A (en) | Formula of compound colla carapaeis corii asini series products and method for producing the same | |
| RU2450825C2 (en) | Using leptin for preventing overweight and compositions containing leptin | |
| CN106036387A (en) | Super chenopodium quinoa willd nutritional packet for promoting growth of children | |
| CN112675194A (en) | Calcium supplement composition | |
| CN114711432A (en) | Water-soluble calcium and preparation method thereof, calcium agent and application of water-soluble calcium |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240418 Address after: 514500 industrial transfer park of Yetang section of Xinghe line, Xingning City, Meizhou City, Guangdong Province Patentee after: GUANGDONG KAIWEN BIOLOGICAL TECHNOLOGY CO.,LTD. Country or region after: China Patentee after: GUANGZHOU KEVIN FOOD CO.,LTD. Address before: Room 1103, Building D, Block A, Wanhao Dongfang Plaza Urban Complex, Economic and Technological Development Zone, Changchun City, Jilin Province, 130000 Patentee before: Jilin Haotai Health Industry Development Co.,Ltd. Country or region before: China Patentee before: GUANGDONG KAIWEN BIOLOGICAL TECHNOLOGY CO.,LTD. Patentee before: GUANGZHOU KEVIN FOOD CO.,LTD. |
|
| TR01 | Transfer of patent right |